Compare AbCellera Biologics Inc (ABCL) vs Public Storage (PSA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Public Storage — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Public Storage trades at $321.39 (market cap $57.71B). The key difference: Public Storage is far larger — about 24.6× AbCellera Biologics Inc's market cap, and Public Storage pays a 3.65% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PSA | |
|---|---|---|
Market Cap | $2.35B | $57.71B |
Sector | Health | Real Estate |
52-Week High | $8.12 | $329.64 |
52-Week Low | $2.78 | $258.44 |
Enterprise Value | $1.99B | $71.96B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Public Storage (PSA) trades at $328.69, near analyst consensus targets, with a slight 0.29% dip. The stock shows strong technical momentum with bullish moving averages and support at $321. Fundamentally, PSA maintains robust profitability with a 39.16% net margin and consistent earnings beats, though valuation multiples like P/E of 33.47 appear elevated. Recent developments include a $1.2B Canadian acquisition and enhanced liquidity facilities, signaling growth initiatives.
Outlook remains positive driven by operational strength and strategic expansions, but risks include high valuation sensitivity and interest rate exposure. Analyst consensus leans Hold (62.86%), with a $330.38 price target suggesting limited near-term upside. Investors should weigh solid fundamentals against premium pricing in a normalized REIT environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
